177 related articles for article (PubMed ID: 19238124)
1. Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol.
de Oliveira IR; Elkis H; Gattaz WF; Chaves A; de Sena EP; de Matos E Souza FG; Campos JA; Bueno JR; E Silva JA; Louzã MR; de Abreu PB
CNS Spectr; 2009 Feb; 14(2):93-102. PubMed ID: 19238124
[TBL] [Abstract][Full Text] [Related]
2. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
[TBL] [Abstract][Full Text] [Related]
4. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
Andrezina R; Josiassen RC; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; Iwamoto T
Psychopharmacology (Berl); 2006 Oct; 188(3):281-92. PubMed ID: 16953381
[TBL] [Abstract][Full Text] [Related]
5. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
[TBL] [Abstract][Full Text] [Related]
6. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S
J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
Daniel DG; Currier GW; Zimbroff DL; Allen MH; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560
[TBL] [Abstract][Full Text] [Related]
8. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.
Tran-Johnson TK; Sack DA; Marcus RN; Auby P; McQuade RD; Oren DA
J Clin Psychiatry; 2007 Jan; 68(1):111-9. PubMed ID: 17284138
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.
Kasper S; Lerman MN; McQuade RD; Saha A; Carson WH; Ali M; Archibald D; Ingenito G; Marcus R; Pigott T
Int J Neuropsychopharmacol; 2003 Dec; 6(4):325-37. PubMed ID: 14609439
[TBL] [Abstract][Full Text] [Related]
11. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
Marder SR; McQuade RD; Stock E; Kaplita S; Marcus R; Safferman AZ; Saha A; Ali M; Iwamoto T
Schizophr Res; 2003 Jun; 61(2-3):123-36. PubMed ID: 12729864
[TBL] [Abstract][Full Text] [Related]
12. Dopamine partial agonists: a new class of antipsychotic.
Lieberman JA
CNS Drugs; 2004; 18(4):251-67. PubMed ID: 15015905
[TBL] [Abstract][Full Text] [Related]
13. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
Kim CY; Chung S; Lee JN; Kwon JS; Kim DH; Kim CE; Jeong B; Jeon YW; Lee MS; Jun TY; Jung HY
Int Clin Psychopharmacol; 2009 Jul; 24(4):181-8. PubMed ID: 19451828
[TBL] [Abstract][Full Text] [Related]
14. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study.
Andrezina R; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; McQuade RD
Curr Med Res Opin; 2006 Nov; 22(11):2209-19. PubMed ID: 17076982
[TBL] [Abstract][Full Text] [Related]
15. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA).
Tandon R; Marcus RN; Stock EG; Riera LC; Kostic D; Pans M; McQuade RD; Nyilas M; Iwamoto T; Crandall DT
Schizophr Res; 2006 May; 84(1):77-89. PubMed ID: 16483745
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
Barbui C; Accordini S; Nosè M; Stroup S; Purgato M; Girlanda F; Esposito E; Veronese A; Tansella M; Cipriani A;
J Clin Psychopharmacol; 2011 Jun; 31(3):266-73. PubMed ID: 21508849
[TBL] [Abstract][Full Text] [Related]
17. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies.
Volavka J; Czobor P; Citrome L; McQuade RD; Carson WH; Kostic D; Hardy S; Marcus R
J Clin Psychiatry; 2005 Nov; 66(11):1362-6. PubMed ID: 16420071
[TBL] [Abstract][Full Text] [Related]
19. Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia.
Docherty JP; Baker RA; Eudicone J; Mathew S; Marcus RN; McQuade RD; Mankoski R
Schizophr Res; 2010 Jul; 120(1-3):199-203. PubMed ID: 20547037
[TBL] [Abstract][Full Text] [Related]
20. Aripiprazole.
McGavin JK; Goa KL
CNS Drugs; 2002; 16(11):779-86; discussion 787-8. PubMed ID: 12383035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]